Sealy Unveils New Sealy® Hybrid Line with Cooling Technology

LAS VEGAS, Jan. 26, 2018 /PRNewswire/ — Tempur Sealy International, Inc. (NYSE: TPX) introduces the new Sealy® Hybrid line leveraging the best technologies from its Response and Conform lines by featuring the responsive support of an innerspring with the conforming comfort of memory foam. Delivering 40 percent more cooling comfort* than before, the Sealy Hybrid line’s DuoChill™ Cooling Sleep System also features twice the cool-to-the-touch technology.

“The new Sealy Hybrid line is the capstone of the unprecedented brand relaunch that rolled out in 2017, and it offers the complete package,” said Rick Anderson, Tempur Sealy EVP and President, North America. “According to our research, hybrid mattress consumers are seeking sturdy support and contouring comfort with real cooling technology. Sealy Hybrid was precisely engineered to meet those needs and deliver the best of both worlds – the perfect balance of soft on top and firm underneath – while offering more cooling benefits than ever.”

New Sealy Hybrid Elevates Category
As Sealy’s coolest hybrid mattress ever, the new Sealy Hybrid line offers cool-to-the-touch Sealy Chill™ Technology in both the top cover panel and on the sleep surface of the memory foam layer to deliver the ultimate climate control experience.

Sealy Hybrid’s Longest Lasting Support Hybrid Ever
Rooted in Sealy’s exclusive Posturepedic Technology™, the new Sealy Hybrid line is Sealy’s most supportive hybrid mattress to date, featuring nested coil technology with 20% more coils in the center to deliver reinforced support where it is needed most, while also including lightly conforming memory foam on the surface to cradle and relieve pressure points. Duraflex™ Coil Edge technology offers better edge support uniquely designed to provide more usable sleeping surface and improved durability.

Best Rated Sealy Hybrid Line of Mattresses
According to a leading consumer publication’s 2016 and 2017 rankings, Sealy Hybrid was the highest rated hybrid mattress. As a trusted leader in the industry, the brand remains grounded in innovation and expertly achieves the perfect combination of delivering a soft yet firm bed that consumers are seeking by combining the exceptional support benefits from the Response line with the enveloping comfort of the Conform line.

The new Sealy Hybrid rounds out Sealy’s reinvigorated product line featuring its three distinct mattresses – Response™, Conform™ and Hybrid™. Each line features a collection with various features to offer a range of price points so consumers can choose the mattress that fits their needs.

For more information on Sealy products, visit www.sealy.com

About the Company
Tempur Sealy International, Inc. (NYSE: TPX) develops, manufactures, and markets mattresses, foundations, pillows and other products. The Company’s products are sold worldwide through third party retailers, its own stores, and online. The Company’s brand portfolio includes many highly recognized brands in the industry, including Tempur®, Tempur-Pedic®, Sealy® featuring Posturepedic® Technology, and Stearns & Foster®. World headquarters for Tempur Sealy International is in Lexington, KY. For more information, visit http://www.tempursealy.com or call 800-805-3635.

Contacts:

Aubrey Moore 
Tempur Sealy Investor Relations
Phone: 800-805-3635
Email: Investor.relations@tempursealy.com 

Rick Maynard 
Tempur Sealy Public Relations
Phone: 859-455-2477
Email: Rick.Maynard@tempursealy.com 

*Based on average length of time to absorb heat versus 2013 and 2015 Sealy Hybrid mattresses.

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/sealy-unveils-new-sealy-hybrid-line-with-cooling-technology-300588454.html

SOURCE Tempur Sealy International, Inc.

Related Links

http://www.tempursealy.com

BioAmber restructures its credit facility with its senior lenders

MONTREAL, Jan. 26, 2018 /PRNewswire/ – BioAmber Inc.  (NYSE: BIOA) (TSX: BIOA), a leader in renewable materials, today announced that its Canadian subsidiary BioAmber Sarnia Inc. (the “company”), has entered into a waiver and amending agreement to its current loan agreement with its senior lending syndicate.

This amendment to the loan agreement removes certain financial covenants under the terms of the loan agreement with the senior lenders, namely a minimum cash requirement and ongoing revenue covenants. 

The senior lenders have also agreed to waive all violations under the loan agreement and the company has agreed to present to the lenders a recapitalization plan by March 15, 2018. In the amendment , the company undertakes  (i) to engage a consultant to monitor its cash flows and to provide to the lenders weekly reports on its activities and monthly financial reports, (ii) to engage an appraiser to conduct a valuation of its Sarnia facility before January 31, 2018, (iii) to postpone any interest and capital payments to its subordinated lenders to the earliest to occur of December 31, 2018, the time at which the secured obligations under the loan agreement are paid in full, and such other date as may be agreed to by the required lenders under the loan agreement, and (iv) not to increase senior management compensation arrangements or pay bonuses to the senior management team, nor make payments other than as contemplated by the company’s weekly cash flow projections.

“Our lending syndicate has been a key supporter of BioAmber from the construction phase through to today.  These amendments eliminate certain restrictive financial covenants that we had in our loan agreement, release a minimum cash requirement and support the overall growth of our business,” said Richard Eno, Chief Executive Officer, BioAmber Inc.

About BioAmber

BioAmber (NYSE: BIOA, TSX: BIOA) is a renewable materials company. Its innovative technology platform combines biotechnology and catalysis to convert renewable feedstock into building block materials that are used in a wide variety of everyday products including plastics, paints, textiles, food additives and personal care products.  For more information visit www.bio-amber.com

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward- looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.   For additional disclosure regarding these and other risks faced by BioAmber, see disclosures contained in BioAmber’s public filings with the SEC and in Canada on SEDAR, including the “Risk Factors” section of BioAmber’s Annual Report on Form 10-K and the most recent quarterly report on Form 10-Q.

SOURCE BioAmber Inc.

Related Links

http://www.bio-amber.com/

Phreesia Named Greenway Marketplace Partner of the Year

NEW YORK, Jan. 26, 2018 /PRNewswire/ — Phreesia, the nation’s leading patient intake management platform, has been named Greenway Health’s Marketplace Partner of the Year for a third time. The award illustrates the strength of the Phreesia-Greenway Health partnership and Phreesia’s commitment to helping healthcare organizations of all sizes to improve the patient experience and enhance care.

“Greenway is proud of all its Marketplace partners and our shared responsibility to enable clinical and financial outcomes for our customers,” said Mark Janiszewski, executive vice president of product management for Greenway Health. “Phreesia rose to the top based on the popularity of its solutions with Greenway Health customers and its collaborative partnership with us delivering an integrated solution that enhances the customer’s experience.”    

According to Greenway Health, Phreesia was selected for the award based on the strength of its intake platform, its robust integrations with Prime Suite and Intergy, and Phreesia’s willingness to work together on various projects. Phreesia sends over 113 million transactions through Greenway’s application programming interface (API) monthly.

Phreesia was also named Greenway Health’s Partner of the Year in 2014 and 2015.

“It’s a tremendous honor to be named Greenway Partner of the Year for a third time,” said Phreesia CEO Chaim Indig. “This recognition is a testament to our strong partnership and our shared goal of enhancing clinical and business outcomes for our mutual clients.”

ABOUT PHREESIA

Phreesia gives healthcare organizations a suite of applications to manage the patient intake process. Our innovative SaaS platform engages patients in their healthcare and provides a modern, consistent experience, while enabling our clients to optimize their staffing and enhance clinical care. To learn more about the benefits Phreesia can bring to your organization, visit phreesia.com.   

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/phreesia-named-greenway-marketplace-partner-of-the-year-300588630.html

SOURCE Phreesia

Related Links

http://phreesia.com

Ronnie Coleman Signature Series® Posts Record Revenue, Prepares for Huge Growth in 2018

LAKE MARY, Fla., Jan. 26, 2018 /PRNewswire/ — Ronnie Coleman Signature Series™ (RCSS) is a brand of sports and fitness supplements that is owned and operated by eight-time Mr. Olympia Ronnie Coleman and his team of industry veterans. Established in 2011, RCSS has become a respected name and brand in the global supplement market by producing useful and trustworthy products with an approach that focuses on the needs of the consumer.

While 2017 produced rocky results for many sports nutrition supplement companies, RCSS closed out 2017 in dynamic fashion by posting its best month since inception that capped off a year-over-year growth figure of 29.3 percent. RCSS owner and CEO Brendan Ahern on RCSS’s record year: “We came into 2017 with a very comprehensive strategy that would require full commitment from every single employee and vendor to work. Our team worked tirelessly to ensure we executed at every level and we did just that. The results are a byproduct of sticking to a plan. We couldn’t be happier with the outcome and look forward to producing greater results next year. “

RCSS is off to a hot start in 2018 with the launch of several new items with an emphasis on their blood flow volumizer aid “Stacked N.O. Liquid Pump Shot™,” which is the first of its kind in a liquid. Always looking to be at the forefront of innovation, RCSS is first to market with this specific blood-volumizing ingredient in a stable liquid format. This easy-to-take flavored shot can be consumed just minutes before training to help produce increased blood flow and aid in expanded blood volume allowing for more water and nutrients to be driven directly into the muscles. This results in better performance as well as a swelling “pump” feeling that any dedicated weightlifter is constantly chasing. Other new product releases include a natural testosterone booster (King Test 8X™), sleep aid capsules (Resurrect P.M.®) and a fast-acting carbohydrate replenishment and hydration powder (King Carb™).

Ahern on the importance of innovation: “A supplement brand’s ability to innovate and be first to market with a product that is new, different and intriguing to the end consumer almost always determines whether or not that brand will continue to be successful. The end consumers in any market always want the latest and greatest … it’s our job to deliver that.”

RCSS is also expanding the headquarters to a much larger facility in Lake Mary, Florida. The new space will include a 3,000-square-foot fitness facility, 8,000-square-foot office space and a 28,000-square-foot warehouse. Also, the HQ build-out will include a media/podcast room as fresh content is a must for brands in the social media-driven world in which we live. The RCSS podcast, aptly named “Ain’t Nothin’ But a Podcast” after one of Coleman’s famous phrases, can be viewed on their official YouTube channel – https://www.youtube.com/user/RCSSTV.

The space seems vital to keep up with the recent growth. “The additional space will give us the opportunity to explore various vertical integrations as well as streamline our current operations. We have no plans to slow down in 2018 that’s for sure,” Ahern said. 

More information about RCSS can be found here on their website – https://RonnieColeman.net.

Media Contact:
Derek Ciocca – CMO
1-888-854-3316
Marketing@ronniecoleman.net

Related Links

Official Website

Official YouTube

Related Video

http://www.youtube.com/watch?v=ChlvUc6TRvw

 

SOURCE Ronnie Coleman Signature Series

PaperWorks $2 million investment in new die-cutter for folding carton litho press in Greensboro, NC

BALA CYNWYD, Pa., Jan. 26, 2018 /PRNewswire/ — PaperWorks Industries has invested $2 million in a new 40-inch sheet-fed Bobst die-cutter for its Greensboro, N.C. facility. The investment is in addition to the recently announced $3 million capital expenditure for its new 10-station folding carton litho press at the same location.

“The new state-of-the-art die-cutter, in tandem with our existing die-cutter, will enable us to accommodate the maximum output from the new folding carton litho press,” explained Clint Rutledge, chief operating officer, PaperWorks. “Additionally, it will support an additional shift to keep up with growing production demands.”

The investment was driven by brand owner demands for shorter runs, but a larger number of SKUs. 

“Brand owners and private label packagers are constantly looking for ways to grab the consumer’s attention and folding cartons play a key role in that. Our printing capability, coupled with the new die-cutter, will help us meet those objectives,” Rutledge said.

The litho press, which the new die-cutter supports, is capable of many value-added enhancements in a single pass that traditionally take two- and three-passes to achieve. These include matte and metallic inks, specialty coatings and pigments—plus seven-color printing. The capability is driven by the press’ unique configuration.

The press also can run extended color gamut (ECG) color reproduction which means that in addition to the traditional cyan, magenta, yellow and black found on traditional presses, orange, green and violet have been added for a total of seven printing stations.  ECG capability cost-effectively delivers higher-impact graphics by delivering expanded color capability in one pass.

This latest investment is in addition to the $60 million the company has spent over the past three years to upgrade its paperboard mills and folding carton converting plants.

About PaperWorks Industries, Inc.
PaperWorks Industries is a leading, integrated North American full-service provider of recycled paperboard and specialized folding cartons for packaging applications. The company also is committed to the highest sustainable forestry and procurement standards. Product certifications include the Forest Stewardship Council (FSC) and 100% Recycled Paperboard Alliance (RPA100). For more information:  www.paperworksindustries.com.

Cision View original content:http://www.prnewswire.com/news-releases/paperworks-2-million-investment-in-new-die-cutter-for-folding-carton-litho-press-in-greensboro-nc-300588667.html

SOURCE PaperWorks Industries, Inc.

Related Links

http://www.paperwrks.com

Medical-Grade Wearable Provider Biotricity Aims to Increase Patient Adherence

REDWOOD CITY, Calif., Jan. 26, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, is poised to change cardiac healthcare into a preventive and cost-savings model that leverages precise biometrics and actionable feedback to motivate patient adherence. With increased adherence, the Company believes that patients with existing chronic conditions can better manage their health and prevent the onset of co-morbid conditions while facilitating a reduction in healthcare costs.
Biotricity is developing a spectrum of real-time and high-precision remote patient monitoring solutions (RPM). The company’s premier product, Bioflux, is a high-precision, single-unit mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients’ ECG information.With shorter time gaps between follow-up appointments, RPM devices can increase patient adherence by shortening the feedback loop and enabling patients to take the necessary action to mitigate negative health outcomes.“When patients can track their progress, and see how certain choices have a direct and positive impact on their health, they are more likely to adhere to treatment plans, engage in their healthcare, and change their behavior,” said Waqaas Al Siddiq, Biotricity Founder and CEO.This kind of proactive approach to healthcare should also lead to a reduction in healthcare costs, both for patients and providers. Chronic conditions necessitate the kind of minute diligence and around-the-clock monitoring that an RPM device can offer; attempting to provide comparative in-facility care for chronic conditions only places an undue burden on an already over-taxed healthcare system. Many patients struggle to find the resources to visit a physician’s office for frequent and routine checkups, which an RPM device could provide accurately and conveniently at home. Biotricity’s development strategy for its RPM solutions is focused on enabling physicians and healthcare providers to receive reimbursement by using existing CPT codes to bill for the company’s solutions.To learn more, visit www.biotricity.com or follow onAbout Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-590-4155
investors@biotricity.com
 

Premier Biomedical, Inc. CEO Letter — January, 2018

DALLAS, Jan. 26, 2018 (GLOBE NEWSWIRE) —Greetings From The CEO And Staff At Premier Biomedical!
It has been a very busy and eventful quarter, and an exceptionally fruitful year, for Premier Biomedical (OTCQB:BIEI).Finance and Stock PerformanceFinancing secured earlier this year has enabled the company to pivot from a pure cancer R&D company (which would remain totally dependent on borrowed money) to a revenue-producing entity with all-natural topical pain relief products.Recently our stock was moved to OTC Pink from OTCQB.  What does this mean to the business?  In effect, nothing.  We will continue to be a fully reporting company with audited financial statements.  The only negative side-effect is that it may become more difficult to borrow money, but our current strategy is to become self-funding as soon as possible, and assume debt only when absolutely necessary.By continuing all financial controls, auditing and reporting, our transition back to OTCQB or other exchanges will be facilitated.Business StructureIn the third quarter of 2016, faced with a high debt load and a depressed stock price, we were forced to explore options where we could quickly transition to a revenue-producing entity.Recognizing the severity of the national crisis of opioid-related drug overdose deaths, we determined that this was a potentially large market for an opioid alternative.  After extensive consideration by our technical staff, we decided that topical hemp oil products were a potential solution to address this pressing national need.Another advantage of topical hemp oil products is that they could be developed, produced and marketed in relatively short time frame in a very cost effective manner.  We also decided that our product focus would be limited to all-natural, 50-state legal, industrial hemp oil products.Very early in 2017, we launched our e-commerce website to sell our first product, a 96-hour topical hemp oil skin patch.  During the year, we grew our product line-up to a total of five topical hemp oil skin products (a 150mg, 10 ml oil-based roll-on, a 120mg, 10 ml water-based roll-on, a 150mg, 30ml spray and a 150mg, 2 oz. ointment).In the fourth quarter, we finalized an agreement with Carl Eller, President of the NFL Retired Players Association.  We hope to develop this relationship into an entrée to current and retired professional sports personnel.Dr. Patricio Reyes, our Chief Medical and Technical Officer, is currently Chief Medical Officer to the NFL Retired Players Association and is on the neurology staff at the Phoenix VA Hospital.  Dr. Reyes took a sampling of our products and an investor presentation of the company to the Philippines last week with the intent of introducing our company and products to the Philippines medical community.In 2018, we intend to focus on the steps necessary to increase the number of major distributors handling our broad topical pain relief product line-up.  Our recent partnership with HealthWarehouse is a major step forward to establishing similar relationships with pharmacies, clinics, physicians’ offices, senior care facilities, etc.As we move forward into 2018, we will be dramatically increasing our sales network through the addition of experienced pharmaceutical representatives.  We are in the process of negotiating agreements to build a sales structure, starting with an experienced National Sales Director (already identified).  We will be rolling out this structure regionally and expanding and improving it as we go.  Updates on our progress in this effort will be provided periodically.We believe that increased product exposure and sales and the resultant revenue generation – which are the fundamentals of building a good business — will lead to a stock resurgence.Immunotherapy and Biologics.We continue to actively seek a partner for our cancer research technology development.  We would consider any proposal, including partnership, licensing or sale that represents value for our investors.We have declined several offers that were not in the best interest of our shareholders.  We have a very promising anti-cancer drug which, in animal tests, has outperformed chemo therapy and competitive drugs currently on the market. These results have been peer-reviewed in prestigious cancer journal articles.  We believe this product has significant value, and should be adequately recognized in any potential agreement.Pain Management.Currently there is a crisis in this country where 60 -70,000 people die annually from drug over-doses linked to prescription pain medications.  We believe that this environment provides a catalyst for the growth of our all-natural, effective, topical pain relief products.An industry study has projected the topical pain relief products market could exceed $5 billion annually by the year 2025.We surveyed the principal competitors’ product offerings and developed proprietary formulations for our initial product, a 96-hour, 50mg hemp oil topical skin patch, as well as the four additional products introduced in 2017.  Customers have reported all of these products as being effective in relieving a variety of pains and discomfort.We initiated the direct sale of our products in January of 2017 via our website, www.painreliefmeds.com.  We then branched out to local pharmacies and pain clinics.  We recently completed negotiations and cemented an agreement with HealthWarehouse, the largest on-line cash-pharmacy in the nation, to market and distribute our products.We have received orders for our products from the UK, France, Canada, Mexico, Australia, and the Netherlands.  We believe this off-shore exposure will continue and possibly result in establishing overseas distributorships.Investor/Public Relations Programs.We have signed an agreement with the New York investor relations firm, New To The Street.  I completed an extensive interview in December, which will be aired January 28, 2018, at 1:30 PM EST.  This program is part of the Fox Business Network which has a potential audience of 90 million homes.  I will appear in five additional segments in 2018, and we will notify our stockholders via our email network.We will continue our relationship with Uptick Newswire and present corporate updates approximately every six weeks on their network and via press releases.We continue our relationship with G S Whitney who has done very good investor relations work in presenting the company to its network of investors worldwide.SUMMARYThis past year, we pivoted the company from a pure R&D focus to a sales-generating product line-up of topical pain relievers which we believe offer superior performance at a competitive price.  All of our products are non-narcotic, all-natural, pesticide- and solvent-free, 50-state legal and drug test safe.Testimonials from our customers indicate effective pain relief for a variety of conditions, including polymyalgia, fibromyalgia, arthritis; neuropathy, migraines, muscle aches, phantom limb pain, etc. (See the Testimonials section on our website Home page, www.painreliefmeds.com).Developing our sales channels in 2018 is expected to broaden our distribution reach.We partnered with HealthWarehouse to expand sales reach and to fight opioid abuse.  We believe this relationship could provide access to many other entities, including senior centers, pharmacies, physicians and hospitals, chiropractors and pain clinics.The addition of Carl Eller provides access for our products to the sports industry.This business would not be possible without the support, dedication and major contributions of all of the people in our organization. Our continued acquisition of superior talent demonstrates a commitment by the staff and the company to our collective future.We thank you, our investors and loyal stockholders, and pledge that we will continue our efforts on your behalf. We thank you for your patience and continued support.Sincerely,William A. Hartman
President and CEO
Premier Biomedical Inc.
(724) 633-7033
PR@premierbiomedical.com
http://www.premierbiomedical.com/
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Source: Uptick Newswire

RLH Corporation Announces Execution of Five Hotel Purchase and Sale Agreements

DENVER, Jan. 26, 2018 (GLOBE NEWSWIRE) — RLH Corporation (NYSE:RLH) today announced the execution of five hotel purchase and sale agreements resulting from the previously disclosed listing for sale of 11 company-owned hotels. The five sales are currently anticipated to close in February or early March, 2018, subject to standard contingencies and closing conditions.
The sale prices contracted on these five assets exceeded the company’s expectations. The real estate market conditions remain robust and RLH Corporation was able to negotiate pricing for these first five hotels reflecting single-digit cap rates. The company expects to maintain Red Lion Hotel franchises going forward on all five of the contracted hotels. Based on these contracts and the current negotiations for remaining hotels in the sales program, the company is happy to reiterate its expectation that aggregate pricing for the 11 hotels will be in the $165 million to $175 million range.“As a key component of our transition to a high-growth franchise company, we are extremely pleased with the initial five contracted sales and the excellent market we are finding for our hotel sales program,” stated Greg Mount, RLH Corporation President and Chief Executive Officer. “We are confident that we will complete the majority of our hotel sales during the first and second quarters of 2018. These sales will allow us to significantly reduce our long-term debt and the expected gains on the assets sales will increase our cash reserves. This clean-up of our balance sheet will further enhance our very strong position as we pursue the aggressive growth of our franchise business.” As the company closes on each individual hotel sale, it plans to disclose details that will allow shareholders and analysts to adjust their models to discontinue the earnings and cash flows from the disposed asset and to reflect the reduction in debt and increase to the company’s cash reserves.In November, the company substantially modified its cost base in anticipation of completing most of its hotel sales in the first half of 2018 and making the transition to operating primarily as a franchise company.  This resulted in anticipated annual expense reductions of $2.5 million.  “We expect to initiate additional cost reductions as we sell hotels in 2018 to further bring our costs in line with typical franchise operations,” said Mount. “We expect franchise segment adjusted EBITDA margins to continue to improve during 2018.”To learn more about franchising with RLH Corporation, visit franchise.rlhco.com.About RLH Corporation
Red Lion Hotels Corporation is an innovative hotel company doing business as RLH Corporation and focuses on the franchising, management and ownership of upscale, midscale and economy hotels. The company focuses on maximizing return on invested capital for hotel owners across North America through relevant brands, industry-leading technology and forward-thinking services. For more information, please visit the company’s website at www.rlhco.com.
Social Media:
www.Facebook.com/myhellorewards
www.Twitter.com/myhellorewards
www.Instagram.com/myhellorewards
www.Linkedin.com/company/rlhco
Investor Relations Contact:
Amy Koch
O: 509-777-6417
C: 917-579-5012
investorrelations@rlhco.com
Media Contact:
Dan Schacter
Director, Social Engagement and Public Relations
509-777-6222
dan.schacter@rlhco.com

Twin Disc, Inc. Announces Fiscal 2018 Second-Quarter Earnings Conference Call and Press Release

RACINE, Wis., Jan. 26, 2018 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ:TWIN), today announced that it will release its fiscal 2018 second-quarter financial results before the market opens on Friday, February 2, 2018.  In conjunction with the earnings release, Twin Disc will be hosting a conference call to discuss these results and to answer questions at 11:00 a.m. Eastern Time on Friday, February 2, 2018.  To participate in the conference call, dial 800-289-0517 five to 10 minutes before the call is scheduled to begin.  A replay will be available from 2:00 p.m. February 2, 2018 until midnight February 9, 2018.  The number to hear the teleconference replay is 844-512-2921.  The access code for the replay is 1970333. 
The conference call will also be broadcast live over the Internet.  To listen to the call via the Internet, access Twin Disc’s website at http://ir.twindisc.com/ and follow the instructions at the web cast link.  The archived web cast will be available shortly after the call on the Company’s website. Twin Disc, Inc. designs, manufactures and sells marine and heavy-duty off-highway power transmission equipment.  Products offered include: marine transmissions, surface drives, propellers and boat management systems, as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches and control systems.  The Company sells its products to customers primarily in the pleasure craft, commercial and military marine markets, as well as in the energy and natural resources, government and industrial markets.  The Company’s worldwide sales to both domestic and foreign customers are transacted through a direct sales force and a distributor network. This press release may contain statements that are forward looking as defined by the Securities and Exchange Commission in its rules, regulations and releases. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. All forward-looking statements are based on current expectations regarding important risk factors including those identified in the Company’s most recent periodic report and other filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those expressed in the forward-looking statements, and the making of such statements should not be regarded as a representation by the Company or any other person that the results expressed therein will be achieved.
Jeffrey S. Knutson
(262) 638-4242

IPG Photonics to Announce Fourth Quarter 2017 Financial Results on February 16

OXFORD, Mass., Jan. 26, 2018 (GLOBE NEWSWIRE) — IPG Photonics Corporation (NASDAQ:IPGP) will release its fourth quarter 2017 financial results before the market opens on Friday, February 16, 2018. The company will hold a conference call to review these results at 10:00 am EST that same day. To access the call, please dial 877-407-6184 in the US or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the company’s website at investor.ipgphotonics.com.
About IPG Photonics CorporationIPG Photonics Corporation is the world leader in high-power fiber lasers and amplifiers. Founded in 1990, IPG pioneered the development and commercialization of optical fiber-based lasers for use in diverse applications, primarily materials processing. Fiber lasers have revolutionized the industry by delivering superior performance, reliability and usability at a lower total cost of ownership compared with conventional lasers, allowing end users to increase productivity and decrease operating costs. IPG has its headquarters in Oxford, Massachusetts, and has additional plants and offices throughout the world. For more information, please visit www.ipgphotonics.com.ContactJames Hillier
Vice President of Investor Relations
IPG Photonics Corporation
508-373-1467
jhillier@ipgphotonics.com